This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
and you are
between 18 and 65
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

This is a study of the sodium channel inhibitor, GSK2339345. Cohort 1 will assess the safety, tolerability and PK of single ascending doses of GSK2339345 administered via an aqueous droplet inhaler in healthy subjects. Cohort 2 will assess the safety, tolerability, and PK of repeat doses of GSK2339345 administered four times a day for two consecutive days via an aqueous droplet inhaler.

Provided treatments

  • Drug: GSK2339345 (Inhaled) Single Dose
  • Other: Placebo (Inhaled) Single Dose
  • Drug: GSK2339345 (Inhaled) Repeat Dose
  • Other: Placebo (Inhaled) Repeat Dose

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01587716. The sponsor of the trial is GlaxoSmithKline and it is looking for 36 volunteers for the current phase.
Official trial title:
A Randomised, Double-blind, Placebo Controlled, Inhaled Single Escalating and Repeat Dose Study Using an Aqueous Droplet Inhaler to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2339345.